Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.

Identifieur interne : 000260 ( Main/Exploration ); précédent : 000259; suivant : 000261

Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.

Auteurs : Avinash K. Shetty [États-Unis]

Source :

RBID : pubmed:30957331

Descripteurs français

English descriptors


DOI: 10.1111/jpc.14392
PubMed: 30957331


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.</title>
<author>
<name sortKey="Shetty, Avinash K" sort="Shetty, Avinash K" uniqKey="Shetty A" first="Avinash K" last="Shetty">Avinash K. Shetty</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30957331</idno>
<idno type="pmid">30957331</idno>
<idno type="doi">10.1111/jpc.14392</idno>
<idno type="wicri:Area/Main/Corpus">000305</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000305</idno>
<idno type="wicri:Area/Main/Curation">000305</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000305</idno>
<idno type="wicri:Area/Main/Exploration">000305</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.</title>
<author>
<name sortKey="Shetty, Avinash K" sort="Shetty, Avinash K" uniqKey="Shetty A" first="Avinash K" last="Shetty">Avinash K. Shetty</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Journal of paediatrics and child health</title>
<idno type="eISSN">1440-1754</idno>
<imprint>
<date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult (MeSH)</term>
<term>Cohort Studies (MeSH)</term>
<term>Drug Therapy, Combination (MeSH)</term>
<term>Female (MeSH)</term>
<term>Follow-Up Studies (MeSH)</term>
<term>Hemangioendothelioma (drug therapy)</term>
<term>Hemangioendothelioma (immunology)</term>
<term>Hemangioendothelioma (pathology)</term>
<term>Humans (MeSH)</term>
<term>Immunocompromised Host (MeSH)</term>
<term>Kasabach-Merritt Syndrome (drug therapy)</term>
<term>Kasabach-Merritt Syndrome (immunology)</term>
<term>Kasabach-Merritt Syndrome (pathology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pneumocystis carinii (isolation & purification)</term>
<term>Pneumonia, Pneumocystis (diagnosis)</term>
<term>Pneumonia, Pneumocystis (drug therapy)</term>
<term>Risk Assessment (MeSH)</term>
<term>Sarcoma, Kaposi (drug therapy)</term>
<term>Sarcoma, Kaposi (immunology)</term>
<term>Sarcoma, Kaposi (pathology)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Sirolimus (adverse effects)</term>
<term>Vincristine (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Appréciation des risques (MeSH)</term>
<term>Association de médicaments (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hémangioendothéliome (anatomopathologie)</term>
<term>Hémangioendothéliome (immunologie)</term>
<term>Hémangioendothéliome (traitement médicamenteux)</term>
<term>Mâle (MeSH)</term>
<term>Pneumocystis carinii (isolement et purification)</term>
<term>Pneumonie à Pneumocystis (diagnostic)</term>
<term>Pneumonie à Pneumocystis (traitement médicamenteux)</term>
<term>Sarcome de Kaposi (anatomopathologie)</term>
<term>Sarcome de Kaposi (immunologie)</term>
<term>Sarcome de Kaposi (traitement médicamenteux)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Sirolimus (effets indésirables)</term>
<term>Sujet immunodéprimé (MeSH)</term>
<term>Syndrome de Kasabach-Merritt (anatomopathologie)</term>
<term>Syndrome de Kasabach-Merritt (immunologie)</term>
<term>Syndrome de Kasabach-Merritt (traitement médicamenteux)</term>
<term>Vincristine (administration et posologie)</term>
<term>Études de cohortes (MeSH)</term>
<term>Études de suivi (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Sirolimus</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Sirolimus</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Hémangioendothéliome</term>
<term>Sarcome de Kaposi</term>
<term>Syndrome de Kasabach-Merritt</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Pneumonia, Pneumocystis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Pneumonie à Pneumocystis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Hemangioendothelioma</term>
<term>Kasabach-Merritt Syndrome</term>
<term>Pneumonia, Pneumocystis</term>
<term>Sarcoma, Kaposi</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Hémangioendothéliome</term>
<term>Sarcome de Kaposi</term>
<term>Syndrome de Kasabach-Merritt</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Hemangioendothelioma</term>
<term>Kasabach-Merritt Syndrome</term>
<term>Sarcoma, Kaposi</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en">
<term>Pneumocystis carinii</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr">
<term>Pneumocystis carinii</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Hemangioendothelioma</term>
<term>Kasabach-Merritt Syndrome</term>
<term>Sarcoma, Kaposi</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Hémangioendothéliome</term>
<term>Pneumonie à Pneumocystis</term>
<term>Sarcome de Kaposi</term>
<term>Syndrome de Kasabach-Merritt</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Cohort Studies</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Risk Assessment</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Appréciation des risques</term>
<term>Association de médicaments</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Sujet immunodéprimé</term>
<term>Études de cohortes</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">30957331</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>10</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>10</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1440-1754</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>55</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2019</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Journal of paediatrics and child health</Title>
<ISOAbbreviation>J Paediatr Child Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>484</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jpc.14392</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shetty</LastName>
<ForeName>Avinash K</ForeName>
<Initials>AK</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-4575-8996</Identifier>
<AffiliationInfo>
<Affiliation>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Australia</Country>
<MedlineTA>J Paediatr Child Health</MedlineTA>
<NlmUniqueID>9005421</NlmUniqueID>
<ISSNLinking>1034-4810</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>5J49Q6B70F</RegistryNumber>
<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C537007">Kaposiform Hemangioendothelioma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006390" MajorTopicYN="N">Hemangioendothelioma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D059885" MajorTopicYN="N">Kasabach-Merritt Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045363" MajorTopicYN="N">Pneumocystis carinii</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011020" MajorTopicYN="N">Pneumonia, Pneumocystis</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012514" MajorTopicYN="N">Sarcoma, Kaposi</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2019</Year>
<Month>01</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2019</Year>
<Month>01</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2019</Year>
<Month>01</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2019</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2019</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">30957331</ArticleId>
<ArticleId IdType="doi">10.1111/jpc.14392</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Caroline du Nord</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Caroline du Nord">
<name sortKey="Shetty, Avinash K" sort="Shetty, Avinash K" uniqKey="Shetty A" first="Avinash K" last="Shetty">Avinash K. Shetty</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000260 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30957331
   |texte=   Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30957331" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020